Table 2.
Comparison of UA and the UA/Cr ratio in patients with LSCC, stratified according to demographics and clinical characteristics.
| UA | UA/Cr ratio | Cr | ||||
|---|---|---|---|---|---|---|
| Mean ± SD | P | Mean ± SD | P | Mean ± SD | P | |
| TNM stage | ||||||
| I (n = 195) | 0.339 ± 0.076 | 4.00 ± 0.99 | 83.88 ± 15.13 | |||
| II (n = 302) | 0.337 ± 0.072 | 4.16 ± 1.09 | 84.65 ± 16.88 | |||
| III (n = 216) | 0.325 ± 0.075 | 4.01 ± 0.96 | 83.81 ± 26.99 | |||
| IV (n = 101) | 0.302 ± 0.079 | <0.05b,c,d,e,f | 3.79 ± 1.03 | <0.05e | 81.08 ± 13.17 | 0.463 |
| T stage | ||||||
| T1 (n = 195) | 0.339 ± 0.076 | 4.00 ± 0.99 | 83.88 ± 15.13 | |||
| T2 (n = 328) | 0.337 ± 0.073 | 4.15 ± 1.08 | 84.79 ± 16.58 | |||
| T3 (n = 239) | 0.323 ± 0.076 | 4.02 ± 0.99 | 82.96 ± 25.91 | |||
| T4 (n = 52) | 0.283 ± 0.070 | <0.05b,c,d,e,f | 3.57 ± 0.99 | <0.05c,e,f | 81.08 ± 14.13 | 0.506 |
| N stage | ||||||
| N0 (n = 722) | 0.331 ± 0.074 | 4.04 ± 1.03 | 84.13 ± 19.88 | |||
| N1 (n = 31) | 0.316 ± 0.080 | 3.94 ± 0.95 | 82.03 ± 16.98 | |||
| N2 (n = 52) | 0.314 ± 0.077 | 3.96 ± 0.96 | 80.44 ± 13.67 | |||
| N3 (n = 9) | 0.374 ± 0.106 | <0.05b,d | 4.64 ± 1.44 | 0.313 | 82.44 ± 11.97 | 0.692 |
| Age | ||||||
| <60 (n = 399) | 0.336 ± 0.075 | 4.18 ± 1.04 | 82.14 ± 13.90 | |||
| ≥60 (n = 415) | 0.325 ± 0.076 | 0.033 | 3.90 ± 1.02 | <0.001 | 85.40 ± 23.37 | 0.015 |
| BMI | ||||||
| <22.94 (413) | 0.329 ± 0.078 | 4.00 ± 1.02 | 84.93 ± 23.83 | |||
| ≥22.94 (401) | 0.331 ± 0.074 | 0.685 | 4.06 ± 1.04 | 0.466 | 83.21 ± 16.54 | 0.229 |
| Hypertension | ||||||
| No (n = 585) | 0.324 ± 0.072 | 4.00 ± 1.03 | 82.58 ± 14.59 | |||
| Yes (n = 229) | 0.347 ± 0.082 | <0.001 | 4.14 ± 1.06 | 0.087 | 86.92 ± 27.92 | 0.026 |
| Smoking | ||||||
| No (n = 244) | 0.331 ± 0.073 | 4.06 ± 1.05 | 83.30 ± 15.50 | |||
| Yes (n = 570) | 0.330 ± 0.076 | 0.749 | 4.03 ± 1.03 | 0.636 | 84.01 ± 20.82 | 0.633 |
| Drinking | ||||||
| No (n = 505) | 0.327 ± 0.073 | 3.96 ± 0.98 | 83.96 ± 16.95 | |||
| Yes (n = 309) | 0.336 ± 0.078 | 0.107 | 4.16 ± 1.11 | 0.010 | 83.53 ± 22.82 | 0.757 |
| Tumour size | ||||||
| ≤2 cm (n = 511) | 0.337 ± 0.072 | 84.28 ± 16.54 | 4.07 ± 1.02 | |||
| >2 cm (n = 303) | 0.318 ± 0.080 | 0.001 | 82.89 ± 23.87 | 0.332 | 3.97 ± 1.07 | 0.183 |
| Operation therapy | ||||||
| Partial laryngectomy (n = 488) | 0.344 ± 0.072 | 85.92 ± 18.16 | 4.03 ± 0.98 | |||
| Total laryngectomy (n = 326) | 0.318 ± 0.076 | <0.001 | 83.48 ± 23.53 | 0.213 | 3.96 ± 1.05 | 0.450 |
| Neck dissection | ||||||
| No (n = 669) | 0.333 ± 0.075 | 4.03 ± 1.03 | 84.61 ± 20.05 | |||
| Yes (n = 145) | 0.324 ± 0.073 | 0.262 | 4.09 ± 0.97 | 0.557 | 81.02 ± 15.58 | 0.070 |
| Tumour subsite | ||||||
| Supraglottic (n = 179) | 0.318 ± 0.076 | 4.08 ± 1.09 | 80.37 ± 17.36 | |||
| Glottis (n = 624) | 0.334 ± 0.074 | 0.013 | 4.03 ± 1.01 | 0.601 | 84.79 ± 19.89 | 0.007 |
| Subglottic (n = 11) | 0.298 ± 0.095 | — | 3.68 ± 1.35 | — | 83.45 ± 15.32 | — |
Data are expressed as mean ± standard deviation (SD). The chi-square test and one-way ANOVA were used. UA: uric acid; Cr: creatinine; BMI: body mass index. a P < 0.05 for the difference between stage I and stage II (1-way ANOVA with the LSD post hoc test). b P < 0.05 for the difference between stage I and stage III (1-way ANOVA with the LSD post hoc test). c P < 0.05 for the difference between stage I and stage IV (1-way ANOVA with the LSD post hoc test). d P < 0.05 for the difference between stage II and stage III (1-way ANOVA with the LSD post hoc test). e P < 0.05 for the difference between stage II and stage IV (1-way ANOVA with the LSD post hoc test). f P < 0.05 for the difference between stage III and stage IV (1-way ANOVA with the LSD post hoc test).